Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -93.22% is 36% below its 5-year average of -68.61%, around the middle of its 5-year range (-165.92%–-8.88%).
As of the fiscal period ended Tuesday, June 30, 2026. 13.20% above its 12-month average of -107.39%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -93.22%.
RETURN ON EQUITY (ROE)
-93.22%
RETURN ON EQUITY (ROE) AVG TTM
-107.39%
RETURN ON EQUITY (ROE) AVG 3Y
-94.38%
RETURN ON EQUITY (ROE) AVG 5Y
-68.61%
RETURN ON EQUITY (ROE) AVG 10Y
-54.21%
RETURN ON EQUITY (ROE) AVG 15Y
-55.16%
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+13.20%
CURRENT VS 3Y AVG
+1.23%
CURRENT VS 5Y AVG
-35.86%
CURRENT VS 10Y AVG
-71.95%
CURRENT VS 15Y AVG
-68.99%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 625 covered companies
CURRENT VS SECTOR MEDIAN
-131.89%
vs the sector median at left
Codexis, Inc.
Market Cap
$151.10M
Return on Equity (ROE)
-93.22%
TTM Avg
-107.39%
3Y Avg
-94.38%
5Y Avg
-68.61%
Market Cap
$151.98M
Return on Equity (ROE)
-21.38%
TTM Avg
-42.33%
3Y Avg
-37.95%
5Y Avg
-45.57%
Market Cap
$152.17M
Return on Equity (ROE)
-155.34%
TTM Avg
-168.75%
3Y Avg
-117.97%
5Y Avg
-104.46%
Market Cap
$149.15M
Return on Equity (ROE)
-183.44%
TTM Avg
-114.28%
3Y Avg
-67.72%
5Y Avg
-46.03%
Market Cap
$148.36M
Return on Equity (ROE)
-397.38%
TTM Avg
-1100.28%
3Y Avg
-310.11%
5Y Avg
-250.84%
Market Cap
$147.97M
Return on Equity (ROE)
-266.86%
TTM Avg
156.76%
3Y Avg
98.17%
5Y Avg
-694.29%
Market Cap
$155.42M
Return on Equity (ROE)
-59.40%
TTM Avg
-255.06%
3Y Avg
-160.44%
5Y Avg
-112.56%
Market Cap
$146.58M
Return on Equity (ROE)
-131.85%
TTM Avg
-36.69%
3Y Avg
-135.43%
5Y Avg
-129.92%
Market Cap
$155.86M
Return on Equity (ROE)
N/A
TTM Avg
13.51%
3Y Avg
15.58%
5Y Avg
15.05%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Codexis, Inc. (CDXS) | $151.10M | -93.22% | -107.39% | -94.38% | -68.61% |
| Anavex Life Sciences Corp. (AVXL)vs › | $151.98M | -21.38% | -42.33% | -37.95% | -45.57% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.17M | -155.34% | -168.75% | -117.97% | -104.46% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $149.15M | -183.44% | -114.28% | -67.72% | -46.03% |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $148.36M | -397.38% | -1100.28% | -310.11% | -250.84% |
| LifeMD, Inc. (LFMDP)vs › | $147.97M | -266.86% | 156.76% | 98.17% | -694.29% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $155.42M | -59.40% | -255.06% | -160.44% | -112.56% |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.58M | -131.85% | -36.69% | -135.43% | -129.92% |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $155.86M | N/A | 13.51% | 15.58% | 15.05% |
| Nyxoah S.A. (NYXH)vs › | $145.11M | -120.33% | -117.87% | -76.44% | -55.77% |
ROE
-93.2%
ROA
-25.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -93.22% |
| 2026-03-31 | -73.99% |
| 2025-12-31 | -87.03% |
| 2025-09-30 | -165.92% |
| 2025-06-30 | -116.80% |
| 2025-03-31 | -150.03% |
| 2024-12-31 | -97.53% |
| 2024-09-30 | -84.59% |
| 2024-06-30 | -124.27% |
| 2024-03-31 | -82.16% |
| 2023-12-31 | -88.02% |
| 2023-09-30 | -89.23% |
| 2023-06-30 | -45.71% |
| 2023-03-31 | -37.97% |
| 2022-12-31 | -23.20% |
| 2022-09-30 | -20.23% |
| 2022-06-30 | -11.88% |
| 2022-03-31 | -12.96% |
| 2021-12-31 | -12.94% |
| 2021-09-30 | -8.88% |
| 2021-06-30 | -14.34% |
| 2021-03-31 | -15.53% |
| 2020-12-31 | -14.11% |
| 2020-09-30 | -22.82% |
| 2020-06-30 | -15.07% |
| 2020-03-31 | -14.59% |
| 2019-12-31 | -11.31% |
| 2019-09-30 | -11.47% |
| 2019-06-30 | -14.28% |
| 2019-03-31 | -22.11% |
| 2018-12-31 | -19.32% |
| 2018-09-30 | -17.25% |
| 2018-06-30 | -33.67% |
| 2018-03-31 | -134.26% |
| 2017-12-31 | -93.68% |
| 2017-09-30 | -132.29% |
| 2017-06-30 | -57.33% |
| 2017-03-31 | -77.43% |
| 2016-12-31 | -44.81% |
| 2016-09-30 | -23.43% |
| 2016-06-30 | -7.08% |
| 2016-03-31 | -55.81% |
| 2015-12-31 | -33.14% |
| 2015-09-30 | -22.24% |
| 2015-06-30 | -88.53% |
| 2015-03-31 | -84.46% |
| 2014-12-31 | -72.48% |
| 2014-09-30 | -115.96% |
| 2014-06-30 | -115.69% |
| 2014-03-31 | -104.06% |
| 2013-12-31 | -99.57% |
| 2013-09-30 | -92.44% |
| 2013-06-30 | -67.39% |
| 2013-03-31 | -46.63% |
| 2012-12-31 | -39.34% |
| 2012-09-30 | -22.17% |
| 2012-06-30 | -22.75% |
| 2012-03-31 | -21.37% |
| 2011-12-31 | -16.12% |
| 2011-09-30 | -11.03% |
| 2011-06-30 | -10.99% |
| 2011-03-31 | -9.85% |
| 2010-12-31 | -7.96% |
| 2010-09-30 | -12.70% |
| 2010-06-30 | -15.97% |
| 2009-12-31 | -19.35% |
